TCF12

Across TCGA pan-cancer cohorts, TCF12 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TCF12 data layer compared with 27 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher TCF12 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TCF12 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

MESO, HNSC, and UCEC are the cancer types where TCF12 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	III,IV	0.069	0.580	<.001	36	view →
HNSC	OS	Median	All	0.132	0.768	<.001	24	view →
UCEC	DFS	Median	II,III,IV	0.937	0.431	.009	24	view →
KIRC	DFS	Median	All	0.062	0.865	<.001	18	view →
LUSC	OS	Median	II,III,IV	0.216	0.732	.018	6	view →
PRAD	OS	Median	All	0.740	0.990	<.001	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TCF12–MESO (OS)

Open the MESO breakdown →